Combined locoregional-immunotherapy for liver cancer Tim F. Greten, Michal Mauda-Havakuk, Bernd Heinrich, Firouzeh Korangy, Bradford J. Wood  Journal of Hepatology  Volume 70, Issue 5, Pages 999-1007 (May 2019) DOI: 10.1016/j.jhep.2019.01.027 Copyright © 2019 Terms and Conditions

Fig. 1 Spontaneous HCC developing in chronically hepatitis infected woodchucks. (A) Contrast-enhanced CT scan shows large heterogenous tumour with robust arterial blood supply (B). Gross pathology of liver and tumour (tumour edges demarcated by white arrows, margins of the tumour behind the liver demarcated by dashed line). HCC, hepatocellular carcinoma. Journal of Hepatology 2019 70, 999-1007DOI: (10.1016/j.jhep.2019.01.027) Copyright © 2019 Terms and Conditions

Fig. 2 Overview of considerations for future research studies combining immunotherapy with locoregional therapies. cTACE, conventional TACE; HIFU, high-intensity focussed ultrasound; IRE, irreversible electroporation; RFA, radiofrequency ablation; TACE, transarterial chemoembolization; TAE, transarterial embolization. Journal of Hepatology 2019 70, 999-1007DOI: (10.1016/j.jhep.2019.01.027) Copyright © 2019 Terms and Conditions

Fig. 3 Tumour response in patient with HCC upon TACE + tremelimumab treatment in lesion not treated by TACE. HCC, hepatocellular carcinoma; TACE, transarterial chemoembolization. Journal of Hepatology 2019 70, 999-1007DOI: (10.1016/j.jhep.2019.01.027) Copyright © 2019 Terms and Conditions